
|Articles|July 15, 2003
Iris-claw myopic IOL shows promise during ongoing FDA trial
Author(s)Cheryl Guttman
San Francisco-In ongoing FDA clinical trial follow-up, the iris-claw myopic IOL (Artisan/Verisyse, Ophtec/AMO) continues to be associated with excellent refractive and visual outcomes along with outstanding safety and high patient satisfaction, said Elizabeth A. Davis, MD, FACS, at the American Society of Cataract and Refractive Surgery annual meeting.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies
3
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
4
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for Demodex Blepharitis
5



























